Karuna Therapeutics Inc

NASDAQ: KRTX
$329.83
+$0.00 (+0.0%)
Closing price April 1, 2024

KRTX Chart and Intraday Price

KRTX Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 33 ARCH STREET, SUITE 3110, BOSTON, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 12,063.83M USD
Shares Outstanding 38,147,700
Karuna Therapeutics Inc is a pioneering biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative medicines for psychiatric and neurological conditions. Its flagship product, KarXT, is an oral treatment aimed at managing acute psychosis in schizophrenia patients, along with addressing cognitive symptoms and dementia-related psychosis, including Alzheimer's disease. The company is also exploring other drug candidates targeting muscarinic receptors for various mental health disorders. Karuna Therapeutics boasts strategic partnerships with notable entities like Eli Lilly and Zai Lab, emphasizing its commitment to advancing mental health care.

KRTX Articles

Another acquisition for Bristol Myers, another acquisition offer from Nano Dimension, and Apple's Watch woes.
The last trading day before the Christmas holiday has stocks headed for a mixed opening following a good, not great, inflation report.